Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03020524 · ClinicalTrials.gov registry record · Early Phase 1
Autologous CD4 T-Cells in HIV (C34-CXCR4)
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT03020524: Completed Early Phase 1 study, sponsored by University of Pennsylvania.
NCT03020524 is a Early Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03020524, a Early Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A single cohort, open-label pilot study of the safety and tolerability of a single infusion of autologous CD4+ T-cells genetically modified with an HR2, C34-peptide conjugated to the CXCR4 N-terminus using a lentiviral vector in HIV-infected subjects. This is a first in human study of C34-CXCR4 T cells
Interventions
- BIOLOGICAL Autologous CD4 T-Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2017-01 |
| Est. Completion | 2020-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03020524
The ClinicalTrials.gov registry entry for NCT03020524 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous CD4 T-Cells is the first listed.
NCT03020524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03020524 about?
NCT03020524 is a clinical study titled "Autologous CD4 T-Cells in HIV (C34-CXCR4)". A single cohort, open-label pilot study of the safety and tolerability of a single infusion of autologous CD4+ T-cells genetically modified with an HR2, C34-peptide conjugated to the CXCR4 N-terminus using a lentiviral vector in HIV-infected subjects. This is a first in human study of C34-CXCR4 T ce...
What is the current status of trial NCT03020524?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2017-01. Estimated completion is 2020-03.
What interventions are being tested in trial NCT03020524?
The interventions under investigation include: Autologous CD4 T-Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03020524?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.